HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.

AbstractOBJECTIVE:
To determine long-term outcomes of patients with ranibizumab-treated retinal vein occlusion (RVO).
DESIGN:
Prospective follow-up of a subset of patients from 2 phase 3 trials.
PARTICIPANTS:
Thirty-four patients with branch RVO (BRVO) and 32 with central RVO (CRVO) who completed the Genentech-sponsored ranibizumab study RVO trials.
METHODS:
Patients seen every month in year 1 and at least every 3 months in year 2 were treated with ranibizumab for intraretinal fluid. Patients requiring injections on consecutive visits were treated with ranibizumab plus scatter photocoagulation.
MAIN OUTCOME MEASURES:
Mean improvement in best-corrected visual acuity (BCVA) and percentage of patients with edema resolution.
RESULTS:
With a mean follow-up of 49.0 months, 17 of 34 BRVO patients (50%) had edema resolution defined as no intraretinal fluid for 6 months or more after the last injection. The last injection was given within 2 years of treatment initiation in 76%. The mean number of injections required in unresolved patients in year 4 was 3.2. In patients with resolved edema mean improvement in BCVA was 25.9 letters versus 17.1 letters (P = 0.09) in unresolved patients, and in both groups, approximately 80% had a final BCVA of 20/40 or better. With a mean follow-up of 49.7 months, 14 of 32 CRVO patients (44%) had edema resolution, with 71% receiving their last injection within 2 years of treatment initiation. The mean number of injections in unresolved patients in year 4 was 5.9. Compared with patients with unresolved CRVO, patients with resolved disease had greater improvement in BCVA (25.2 vs. 4.3 letters; P = 0.002), and a greater percentage had a final BCVA of 20/40 or better (64.3% vs. 27.8%; P = 0.04). Nine patients with BRVO and 9 with CRVO received scatter photocoagulation, and with mean follow-up of 9 months (BRVO) and 11 months (CRVO) after last laser, only 1 in each group had resolution of edema.
CONCLUSIONS:
Long-term outcomes in BRVO patients treated with ranibizumab were excellent, and although half still required occasional injections after 4 years, they maintained good visual potential. A substantial minority (44%) of patients with ranibizumab-treated CRVO had edema resolution and a good outcome within 4 years, but most (56%) still required frequent injections, had reduced visual potential, and have a guarded prognosis.
AuthorsPeter A Campochiaro, Raafay Sophie, Joel Pearlman, David M Brown, David S Boyer, Jeffrey S Heier, Dennis M Marcus, Leonard Feiner, Arun Patel,
JournalOphthalmology (Ophthalmology) Vol. 121 Issue 1 Pg. 209-19 (Jan 2014) ISSN: 1549-4713 [Electronic] United States
PMID24112944 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial)
CopyrightCopyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Ranibizumab
Topics
  • Aged
  • Angiogenesis Inhibitors (adverse effects, therapeutic use)
  • Antibodies, Monoclonal, Humanized (adverse effects, therapeutic use)
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Intravitreal Injections
  • Laser Coagulation
  • Macular Edema (drug therapy, physiopathology)
  • Male
  • Middle Aged
  • Prospective Studies
  • Ranibizumab
  • Retinal Vein Occlusion (drug therapy, physiopathology)
  • Single-Blind Method
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)
  • Visual Acuity (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: